The July 2010 issue of Cosmetic Surgery Times reports on some of the latest news in the U.S. injectables market, including FDA-approved lidocaine hyaluronic acid fillers and fillers that may soon reach the American market.
Three injectables received FDA approval in February 2010 for lidocaine versions in the U.S.: Juvederm XC, Restylane-L, and Perlane-L. Lidocaine is a local anesthetic that is injected directly into the body and decreases pain by temporarily numbing the injection area, according to WebMD.
Dr. Michael H. Gold, a clinical assistant professor of dermatology at Vanderbilt University School of Medicine and School of Nursing, says that the products performed similarly to their lidocaine-free predecessors in terms of efficacy and safety. “The incorporation of lidocaine has surely provided a higher comfort level for patients [in the clinical trials],” he adds.
Based on his clinical experience, Dr. Gold reports that when a patient undergoes an injection that includes even a small percentage of lidocaine that most patients say they barely feel the second injection. “To me that is the home run of lidocaine in these fillers,” he says.
In other injectable news, a filler that will soon reach the American market is Belotero Balance for nasolabial folds correction, which Dr. Gold says is awaiting FDA approval. Belotero Balance was first introduced in Germany in 2005.
Learn more about Juvederm and Restylane in the Twin Cities.
Read more about the latest in injectables online at Modern Medicine: “Fillers with lidocaine among latest injectable advancements.”
